Document Detail


Pegvisomant: new preparation. A last resort in acromegaly.
MedLine Citation:
PMID:  15751152     Owner:  HSR     Status:  MEDLINE    
Abstract/OtherAbstract:
(1) The first-line treatment for acromegaly is transsphenoidal surgery. As an adjunct to surgery, and for patients with inoperable tumours, the first-line drug therapy is a somatostatin analogue (octreotide or lanreotide). (2) Pegvisomant, a growth hormone (GH) receptor antagonist, is licensed for patients who have a poor response to surgery and/or radiation therapy and in whom somatostatin analogue therapy has failed. (3) There are no published comparative trials evaluating pegvisomant as alternative for patients who have already tried a somatostatin analogue. Most of the evaluation data comes from a single randomised, placebo-controlled trial in 112 patients treated for three months. It showed that pegvisomant, at a dose of 10 mg to 20 mg/day subcutaneously, normalised the level of insulin-like growth factor type 1 (IGF-1) and improved some symptoms. However, the patients were very heterogeneous, and no information was provided on the efficacy of previous treatments. This trial does not provide enough evidence to support the approved indication. (4) Pegvisomant lowers the IGF-1 level but also increases the GH level. An increase in the size of the pituitary adenoma, due to the resulting hyperfunctioning, was observed in four of the 160 patients treated in clinical trials. (5) Evaluation data on pegvisomant does not resolve the question of possible hepatic toxicity. (6) In practice, pegvisomant therapy is justified for patients with serious complications of acromegaly and who have no other treatment options. But the patients concerned, who are few in number, must be closely monitored and included in an appropriate register.
Authors:
-
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  14     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-03-07     Completed Date:  2005-03-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  France    
Other Details:
Languages:  eng     Pagination:  10-3     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / drug therapy*,  radiotherapy,  surgery
Adenoma / surgery
Drug Approval
Europe
Human Growth Hormone / administration & dosage,  adverse effects,  analogs & derivatives,  secretion,  therapeutic use*
Humans
Octreotide / administration & dosage,  adverse effects,  therapeutic use
Randomized Controlled Trials as Topic
Somatostatin / administration & dosage,  adverse effects,  analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antioxidative polyphenols from berries of Pimenta dioica.
Next Document:  Antitumor effect and apoptosis induction in human cancer cell lines by BRM-SJS